Abvc Biopharma (ABVC) Other Non-Current Liabilities (2019 - 2026)
Abvc Biopharma's (ABVC) quarterly Other Non-Current Liabilities came in at $35404.0 in Q3 2025, up 37.87% YoY from $25680.0 in Q3 2024, and down 15.06% on a QoQ basis from $41680.0 in Q2 2025.
Abvc Biopharma (ABVC) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 7 years of Other Non-Current Liabilities data on file, last reported at $35404.0 in Q3 2025.
- Quarterly Other Non-Current Liabilities rose 37.87% year-over-year to $35404.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $35404.0 (up 37.87% YoY) and the FY2024 annual result came in at $21680.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities eased to $35404.0 in Q3 2025, from $41680.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $41680.0 in Q2 2025 to a low of $5680.0 in Q2 2023.
- A 5-year average of $17133.9 and a median of $12880.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 55.9% — and 2024, when it soared 387.32%.
- Tracing ABVC's Other Non-Current Liabilities over 5 years: stood at $10580.0 in 2021, then slipped by 24.57% to $7980.0 in 2022, then surged by 171.68% to $21680.0 in 2023, then changed by 0.0% to $21680.0 in 2024, then soared by 63.3% to $35404.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $35404.0 (Q3 2025), $41680.0 (Q2 2025), and $21680.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31,167.00 |
| Sep 30, 2025 | 35,404.00 |
| Jun 30, 2025 | 41,680.00 |
| Mar 31, 2025 | 21,680.00 |
| Dec 31, 2024 | 21,680.00 |
| Sep 30, 2024 | 25,680.00 |
| Jun 30, 2024 | 27,680.00 |
| Mar 31, 2024 | 21,680.00 |
| Dec 31, 2023 | 21,680.00 |
| Sep 30, 2023 | 5,680.00 |
| Jun 30, 2023 | 5,680.00 |
| Mar 31, 2023 | 7,480.00 |
| Dec 31, 2022 | 7,980.00 |
| Sep 30, 2022 | 12,880.00 |
| Jun 30, 2022 | 11,980.00 |
| Mar 31, 2022 | 7,980.00 |
| Dec 31, 2021 | 10,580.00 |
| Sep 30, 2021 | 9,880.00 |
| Jun 30, 2021 | 17,180.00 |
| Mar 31, 2021 | 11,080.00 |